Post-transplant diabetes mellitus (PTDM) in heart recipients.
In conclusion, comparative clinical studies with tacrolimus in heart recipients tend to show a similar or increased diabetogenic potential compared with cyclosporine-ME-based therapy. However, these changes are often accompanied by a reduced effect on lipid metabolism and hypertension suggesting a superior cardiovascular risk profile. The superior control of acute rejection also positions tacrolimus as an attractive alternative to cyclosporine for heart recipients.
Garlicki
Mirosław
M
MSWiA Hospital, Warsaw, Poland. kardiochirurgia@cskmswia.pl
D065095:Calcineurin Inhibitors; D003920:Diabetes Mellitus / Q000209:etiology*; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D012307:Risk Factors
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents